With six acquisitions already on the books in 2015, Teva Pharmaceutical Industries (NYSE: TEVA) announced it would pay $2.3 billion for Representaciones e Investigaciones Médicas (Rimsa), a leading pharmaceutical manufacturing and distribution company in Mexico. Also associated with this deal is a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe. With this acquisition, Teva becomes one of the top pharmaceutical companies in Mexico, which is the second largest market in Latin America and one of the top five emerging markets globally. The company expects the deal will yield substantial and achievable synergies and offer a platform for growth in the region.
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
